share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  2024/08/07 21:01

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has entered into a securities purchase agreement on August 6, 2024, for a private placement offering priced at a 10% premium to the market closing price. The company will issue 800,000 ordinary shares and accompanying warrants at $0.75 per unit, with the warrants having a 5-year term and identical exercise price.Notably, company insiders including the CEO, CFO, CMO, and CEO's family members, along with existing shareholders, are participating in this offering. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. Proceeds will be used for general corporate and working capital purposes.The warrants will be immediately exercisable upon issuance and may be exercised on a cashless basis if no effective registration statement is in place. The offering is being conducted under Section 4(a)(2) of the Securities Act and Regulation D exemptions.
NeuroSense Therapeutics has entered into a securities purchase agreement on August 6, 2024, for a private placement offering priced at a 10% premium to the market closing price. The company will issue 800,000 ordinary shares and accompanying warrants at $0.75 per unit, with the warrants having a 5-year term and identical exercise price.Notably, company insiders including the CEO, CFO, CMO, and CEO's family members, along with existing shareholders, are participating in this offering. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. Proceeds will be used for general corporate and working capital purposes.The warrants will be immediately exercisable upon issuance and may be exercised on a cashless basis if no effective registration statement is in place. The offering is being conducted under Section 4(a)(2) of the Securities Act and Regulation D exemptions.
NeuroSense Therapeutics於2024年8月6日簽署了一份證券購買協議,進行定向增發,發行價格爲市場收盤價的10%溢價。該公司將發行800,000股普通股和附帶Warrants,每單位價格爲0.75美元,Warrants的有效期爲5年,行使價格相同。值得注意的是,包括CEO、CFO、CMO及其家屬在內的公司內部人士,以及現有股東,都參與了本次募資。定向增發預計將在2024年8月12日當週完成,具體取決於通常的完工條件。籌集的資金將用於一般公司和營運資金目的。Warrants將在發行後立即可行使,並且如果沒有有效的註冊聲明,可以以無現金方式行使。該募資是在《證券法》第4(a)(2)節及D條款豁免下進行的。
NeuroSense Therapeutics於2024年8月6日簽署了一份證券購買協議,進行定向增發,發行價格爲市場收盤價的10%溢價。該公司將發行800,000股普通股和附帶Warrants,每單位價格爲0.75美元,Warrants的有效期爲5年,行使價格相同。值得注意的是,包括CEO、CFO、CMO及其家屬在內的公司內部人士,以及現有股東,都參與了本次募資。定向增發預計將在2024年8月12日當週完成,具體取決於通常的完工條件。籌集的資金將用於一般公司和營運資金目的。Warrants將在發行後立即可行使,並且如果沒有有效的註冊聲明,可以以無現金方式行使。該募資是在《證券法》第4(a)(2)節及D條款豁免下進行的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息